Immunovia

Company Overview

Founded in 2007 as a spinout from the Center for Translational Cancer Research (Sweden), Immunovia AB is commercializing an immunoaffinity MS-based platform technology. A global proteome survey (GPS), the platform uses antibodies that bind to short amino acid sequences (i.e., motifs) that may be present in more than one protein. The company’s IMMray, core platform technology which is based on antibody microarray analysis can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray PS (Proteome Survey).

GPS can be used as a sample preparation method for MS-based diagnostics and life science research. It allows researchers to isolate proteins without knowing the specific protein in advance. The advantage is creating a workflow that is targeted but also allows for discovery.

The first application for the technology is to use the proteomics profiles generated to grade difficult-to-grade tumors, such as Grade 2 breast cancer or prostate cancers.

A second application for GPS is in affinity proteomics, where it can overcome the key bottleneck of limited access to high-performing antibodies. GPS allows global proteome analysis using only a limited set of antibodies.

Company's Business Segments

• Blood-based Testing : The company provides blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.